Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment

Bob Löwenberg • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses developments in newly diagnosed acute myeloid leukemia (AML) therapy in Europe from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Löwenberg explains how these new therapies may replace or add value to the standard 7+3 chemotherapy backbone, and highlights the need for multinational cooperation to recruit sufficient numbers of patients to trials.

More from Bob Löwenberg

1:28
Bob Löwenberg's perspective on CAR-T and immunotherapy for AML
Bob Löwenberg • 24 Feb 2019
1:02
Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results
Bob Löwenberg • 24 Feb 2019
3:18
How can we tackle treatment failure in ALL?
Bob Löwenberg • 16 Apr 2018
4:57
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
Bob Löwenberg • 19 Feb 2017

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals